AzTrials
AzTrials

Kidney CancerPODRACINGNCT06536439

Planning Operative Strategy Using a Digital Renal Artery Clamping Tool

A study testing Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT) and RAPN (DIPLANN + CT) in people with Kidney Cancer and Kidney Neoplasms, run by University Hospital, Ghent at 5 sites in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Kidney Cancer, Kidney Neoplasms, Kidney Diseases
What is being tested?
Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT) and RAPN (DIPLANN + CT)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
235 participants
Where
5 sitesBelgium
Study dates
27 Jun 2024to 1 Jan 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • aged 18 years or above
  • cT1-2 N0 M0 renal mass
  • planned to undergo RAPN
  • multiphase CT scan with arterial phase available
  • voluntary given and written informed consent
  • sufficient in at least one of the study languages: Dutch, English, French
  • For the primary objective, SC needs to be deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed by an independent surgeon (between inclusion and randomization) who will not be involved in the RAPN surgical procedure, in order to be included in the analysis set. On the DIPLANN tool, SC is deemed feasible if >= 90% tumor ischemia and <= 70% renal parenchyma ischemia can be achieved. If these criteria are met, but it is technically or anatomically not feasible according to the independent surgeon to perform SC, he can deviate from these criteria and thus claim SC is not deemed possible. The results for the total population (patients in which SC is deemed possible AND impossible pre-operatively by an independent surgeon) will also be analyzed as a secondary objective.

Who cannot join

  • > 3 ipsilateral renal masses
  • women who are pregnant or breastfeeding
  • previous renal surgery that is expected to complicate renal cancer surgery
  • cT ≥ 3
  • planned off-clamp resection
  • cognitive disorder which impedes with completing study questionnaires

Trial locations and contacts

5 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Joris Vangeneugden, MD contact

+32 9 332 22 76

joris.vangeneugden@ugent.be

Charles Van Praet, MD, PhD contact

+32 9 332 22 76

charles.vanpraet@uzgent.be

5 sites in 1 country

Belgium5 sites, 5 recruiting
  • AZORG

    Aalst, 9300

    Alexandre Mottrie, +3253724448, urologie.aalst@azorg.be

    Alexandre Mottrie

    Recruiting
  • AZ Sint-Jan

    Bruges, 8000

    Christophe Ghysel, +3250452530, urologie@azsintjan.be

    Christophe Ghysel

    Recruiting
  • ZOL

    Genk, 3600

    Bernard Bynens, +3289808380, secretariaat.urologie@zol.be

    Bernard Bynens

    Recruiting
  • AZ Maria Middelares

    Ghent, 9000

    Karel Decaestecker, MD, PhD, +32 9 246 46 46, secretariaat.urologie@mijnziekenhuis.be

    Karel Decaestecker, MD, PhD

    Recruiting
  • Ghent University Hospital

    Ghent, 9000

    Charles Van Praet, MD, PhD, +32 9 332 22 76, charles.vanpraet@uzgent.be

    Charles Van Praet, MD, PhD

    Recruiting

Other trials in Belgium

About this study

Official title: Planning Operative Strategy Using a Digital Renal Artery Clamping Tool: a Randomized Controlled Trial Evaluating the DIPLANN 3D Model for Selective Arterial Clamping During Robot-Assisted Partial Nephrectomy

A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.

Experimental group: the use of the DIPLANN-tool + conventional computed tomography (CT) imaging for preoperative planning and perioperative guidance during RAPN.

Read more

Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance during RAPN (= current standard of care).

The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.

Read the detailed description

BACKGROUND:

For patients diagnosed with localized kidney cancer, two main options exist to surgically remove the kidney tumor. During radical nephrectomy (RN), the entire kidney is removed. During partial nephrectomy (PN), only the tumor is resected, safeguarding the function of the remaining healthy kidney tissue. This last procedure is preferred, but not always technically feasible. To resect only the tumor, a balance has to be found in the clamping approach: clamping the blood supply to the kidney assures bloodless tumor resection, yet compromises the postoperative renal function due to the temporary ischemia. Tumor resection without clamping on the other hand, might lead to substantial blood loss. That is why "selective clamping" (SC) is proposed. In this approach, only those selective arteries are clamped that perfuse the zone including the tumor. The main drawback of this strategy is that it is often not clear which arteries should be clamped based on standard preoperative imaging, while misjudgment can lead to a high-risk surgery with excessive bleeding or prolonged ischemia time. Therefore, RN is currently recommended when PN is considered not feasible. Better prediction of individual kidney perfusion will allow to perform more frequently a PN and thus save healthier kidney tissue. Additionally, it is difficult for patients to assess their own individual oncological situation based on 2D CT images.

With this project, the investigators want to offer the surgeon an easy-to-use virtual planning tool that facilitates the decision-making process regarding the feasibility of PN and the corresponding optimal clamping strategy. This tool uses virtual 3D models based on CT scans, to visualize precise information on the different anatomical structures and perfusion zones. This may also improve patients' understanding of their own individual situation. The proposed new tool (DIPLANN-tool) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.

DESIGN:

A confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.

Experimental group: the use of the DIPLANN model + conventional CT imaging for preoperative planning and perioperative guidance.

Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance (= current standard of care).

METHODOLOGY:

Sample size calculation: 235 patients.

Patients will be randomized according to a 1:1 allocation ratio to either the experimental group (the DIPLANN-tool in combination with conventional CT imaging) or the control group (conventional CT imaging alone), using permuted block randomization with blocks of varying size.

Randomization will be stratified on the following variables:

  • Whether SC is deemed possible according to the DIPLANN-tool in combination with conventional CT imaging or on conventional CT imaging alone, as assessed by an independent surgeon (between inclusion and randomization) who will not be not involved in the RAPN surgical procedure (yes vs no).
  • Hospital where surgery is performed.
  • PADUA classification (low (<8) and intermediate (8-9) vs high-risk (>9)). In case of multiple masses, the mass with the highest individual PADUA classification will be used.

PRIMARY OBJECTIVE:

To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery and in whom SC is deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed between inclusion and randomization by an independent surgeon.

SECONDARY OBJECTIVES:

  • To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery.
  • To compare the DIPLANN-tool in combination with conventional CT imaging to conventional CT imaging alone with respect to: patients' health, patients' insight, and surgeons' benefits.

ENDPOINTS:

The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.

Extended listing of all outcome measures: see below.

Being tested
Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT), RAPN (DIPLANN + CT), Pre-operative explanation of the procedure (CT only), Pre-operative surgical planning (CT only)
Keywords
Kidney Cancer, Renal Cell Carcinoma, Minimally Invasive Surgery, Robot-Assisted Surgery, Robot-Assisted Partial Nephrectomy, RAPN, 3D, Perfusion Zone
Medical subject headings
Kidney Neoplasms, Kidney Diseases, Carcinoma, Renal Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pre-operative explanation of the procedure (DIPLANN + CT)Device

    Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.

  • Pre-operative surgical planning (DIPLANN + CT)Device

    Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.

  • RAPN (DIPLANN + CT)Procedure or surgery

    Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.

  • Pre-operative explanation of the procedure (CT only)Device

    Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.

  • Pre-operative surgical planning (CT only)Device

    Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.

  • RAPN (CT only)Procedure or surgery

    Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.

Study groups in NCT06536439
Study groupRoleWhat they receive
DIPLANN-tool + conventional CT imagingExperimentalPre-operative planning and peri-operative guidance with DIPLANN-tool and conventional CT imaging.
Receives: Device: Pre-operative explanation of the procedure (DIPLANN + CT); Device: Pre-operative surgical planning (DIPLANN + CT); Procedure: RAPN (DIPLANN + CT)
Conventional CT imaging aloneActive comparatorPre-operative planning and peri-operative guidance with conventional CT imaging alone (standard of care).
Receives: Device: Pre-operative explanation of the procedure (CT only); Device: Pre-operative surgical planning (CT only); Procedure: RAPN (CT only)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Selective clamping

    Planning and performing as planned a selective clamping (SC) strategy (considered by the surgeon at the end of surgery, objectified pre- and postoperatively through online assessment on study website and controlled through video-analysis): planning SC and performing the planned SC strategy = positive outcome; planning SC and performing another SC strategy or full clamping (FC) = negative outcome; planning FC = negative outcome.

    Measured: During surgery

Secondary outcomes (4)
  1. eGFR 6 months

    Change in eGFR at 6 months after surgery compared to eGFR preoperatively.

    Measured: 6 months postoperatively

  2. Clamping strategy

    Clamping strategy performed (selective clamping or full clamping).

    Measured: During surgery

  3. Hilar dissection time

    Time to dissect hilum (minutes) as analyzed on postoperative surgical video analysis.

    Measured: During surgery

  4. Conversion to full clamp

    Conversion from SC to FC.

    Measured: During surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2024
  2. Study start27 Jun 2024
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion1 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.
Masking
None (open label)
Enrolment
235 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06536439
Sponsor's protocol ID
ONZ-2023-0558
Acronym
PODRACING
Status last verified
Mar 2025
First submitted
15 Jul 2024
Last updated
1 Apr 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Vangeneugden J, Vermijs S, De Backer P, Berquin C, Lumen N, De Kuyper P, Raskin Y, Bynens B, Baekelandt F, Ghysel C, Peeren F, De Groote R, De Naeyer G, Mottrie A, De Buyser S, De Visschere P, Debbaut C, Decaestecker K, Van Praet C. Clinical trial protocol of PODRACING: A randomized controlled trial evaluating 3D perfusion zone models for selective arterial clamping during robot-assisted partial nephrectomy. BJUI Compass. 2026 Mar 30;7(4):e70191. doi: 10.1002/bco2.70191. eCollection 2026 Apr.

    PubMed 42022229
  • Vangeneugden J, Vermijs S, De Backer P, Hemeryck B, Berquin C, De Visschere P, Decaestecker K, Debbaut C, Van Praet C. Three-dimensional Perfusion-zone Models Allow More Selective Clamping During Robot-assisted Partial Nephrectomy: Brief Report on a Retrospective Analysis. Eur Urol Open Sci. 2025 Nov 5;82:128-130. doi: 10.1016/j.euros.2025.10.013. eCollection 2025 Dec.

    PubMed 41280160

Questions about this trial

What is this clinical trial studying?

A study testing Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT) and RAPN (DIPLANN + CT) in people with Kidney Cancer and Kidney Neoplasms, run by University Hospital, Ghent at 5 sites in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 1 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Joris Vangeneugden, MD (+32 9 332 22 76, joris.vangeneugden@ugent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Selective clamping (time frame: During surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06536439, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in